 In January 2015, the FDA approved the use of secukinumab (trade name Cosentyx), an IL-17 inhibiting monoclonal antibody, for the treatment of moderate to severe plaque psoriasis.In addition, Cosentyx has been approved in Japan for use in treating psoriatic arthritis.The anti-IL-23 antibody ustekinumab can also be used to effectively treat psoriasis by reducing IL-17.